Cargando…
P491: DAY 14 MEASURABLE RESIDUAL DISEASE ASSESSMENT PREDICTS TREATMENT OUTCOMES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH INTENSIVE CHEMOTHERAPY - RESULTS OF THE PALG-AML1/2016 STUDY
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428723/ http://dx.doi.org/10.1097/01.HS9.0000968872.72243.64 |
| _version_ | 1785090537500442624 |
|---|---|
| author | Wierzbowska, Agnieszka Pluta, Agnieszka Czyz, Anna Czemerska, Magdalena Mikulski, Damian Stelmach, Piotr Libura, Marta Giebel, Sebastian Kopinska, Agnieszka Wozniczka, Krzysztof Helbig, Grzegorz Wojcik, Karol Razny, Malgorzata Sobas, Marta Wróbel, Tomasz Szczepaniak, Andrzej Gil, Lidia Dutka, Magdalena Bieniaszewska, Maria Maciej Zaucha, Jan Gromek, Tomasz Hus, Marek Cichocka, Edyta Halka, Janusz Patkowska, Elzbieta Wozniak, Jolanta Obara, Agata Kopacz, Agnieszka Dulik, Katarzyna Holowiecki, Jerzy Soin, Michał Fendler, Wojciech Rustani, Andi Kaner, Justin Mencia-Trinchant, Nuria Desai, Pinkal Lee, Sangmin Samuel, Michael Ritchie, Ellen Guzman, Monica Roboz, Gail |
| author_facet | Wierzbowska, Agnieszka Pluta, Agnieszka Czyz, Anna Czemerska, Magdalena Mikulski, Damian Stelmach, Piotr Libura, Marta Giebel, Sebastian Kopinska, Agnieszka Wozniczka, Krzysztof Helbig, Grzegorz Wojcik, Karol Razny, Malgorzata Sobas, Marta Wróbel, Tomasz Szczepaniak, Andrzej Gil, Lidia Dutka, Magdalena Bieniaszewska, Maria Maciej Zaucha, Jan Gromek, Tomasz Hus, Marek Cichocka, Edyta Halka, Janusz Patkowska, Elzbieta Wozniak, Jolanta Obara, Agata Kopacz, Agnieszka Dulik, Katarzyna Holowiecki, Jerzy Soin, Michał Fendler, Wojciech Rustani, Andi Kaner, Justin Mencia-Trinchant, Nuria Desai, Pinkal Lee, Sangmin Samuel, Michael Ritchie, Ellen Guzman, Monica Roboz, Gail |
| author_sort | Wierzbowska, Agnieszka |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10428723 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104287232023-08-17 P491: DAY 14 MEASURABLE RESIDUAL DISEASE ASSESSMENT PREDICTS TREATMENT OUTCOMES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH INTENSIVE CHEMOTHERAPY - RESULTS OF THE PALG-AML1/2016 STUDY Wierzbowska, Agnieszka Pluta, Agnieszka Czyz, Anna Czemerska, Magdalena Mikulski, Damian Stelmach, Piotr Libura, Marta Giebel, Sebastian Kopinska, Agnieszka Wozniczka, Krzysztof Helbig, Grzegorz Wojcik, Karol Razny, Malgorzata Sobas, Marta Wróbel, Tomasz Szczepaniak, Andrzej Gil, Lidia Dutka, Magdalena Bieniaszewska, Maria Maciej Zaucha, Jan Gromek, Tomasz Hus, Marek Cichocka, Edyta Halka, Janusz Patkowska, Elzbieta Wozniak, Jolanta Obara, Agata Kopacz, Agnieszka Dulik, Katarzyna Holowiecki, Jerzy Soin, Michał Fendler, Wojciech Rustani, Andi Kaner, Justin Mencia-Trinchant, Nuria Desai, Pinkal Lee, Sangmin Samuel, Michael Ritchie, Ellen Guzman, Monica Roboz, Gail Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10428723/ http://dx.doi.org/10.1097/01.HS9.0000968872.72243.64 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Wierzbowska, Agnieszka Pluta, Agnieszka Czyz, Anna Czemerska, Magdalena Mikulski, Damian Stelmach, Piotr Libura, Marta Giebel, Sebastian Kopinska, Agnieszka Wozniczka, Krzysztof Helbig, Grzegorz Wojcik, Karol Razny, Malgorzata Sobas, Marta Wróbel, Tomasz Szczepaniak, Andrzej Gil, Lidia Dutka, Magdalena Bieniaszewska, Maria Maciej Zaucha, Jan Gromek, Tomasz Hus, Marek Cichocka, Edyta Halka, Janusz Patkowska, Elzbieta Wozniak, Jolanta Obara, Agata Kopacz, Agnieszka Dulik, Katarzyna Holowiecki, Jerzy Soin, Michał Fendler, Wojciech Rustani, Andi Kaner, Justin Mencia-Trinchant, Nuria Desai, Pinkal Lee, Sangmin Samuel, Michael Ritchie, Ellen Guzman, Monica Roboz, Gail P491: DAY 14 MEASURABLE RESIDUAL DISEASE ASSESSMENT PREDICTS TREATMENT OUTCOMES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH INTENSIVE CHEMOTHERAPY - RESULTS OF THE PALG-AML1/2016 STUDY |
| title | P491: DAY 14 MEASURABLE RESIDUAL DISEASE ASSESSMENT PREDICTS TREATMENT OUTCOMES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH INTENSIVE CHEMOTHERAPY - RESULTS OF THE PALG-AML1/2016 STUDY |
| title_full | P491: DAY 14 MEASURABLE RESIDUAL DISEASE ASSESSMENT PREDICTS TREATMENT OUTCOMES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH INTENSIVE CHEMOTHERAPY - RESULTS OF THE PALG-AML1/2016 STUDY |
| title_fullStr | P491: DAY 14 MEASURABLE RESIDUAL DISEASE ASSESSMENT PREDICTS TREATMENT OUTCOMES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH INTENSIVE CHEMOTHERAPY - RESULTS OF THE PALG-AML1/2016 STUDY |
| title_full_unstemmed | P491: DAY 14 MEASURABLE RESIDUAL DISEASE ASSESSMENT PREDICTS TREATMENT OUTCOMES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH INTENSIVE CHEMOTHERAPY - RESULTS OF THE PALG-AML1/2016 STUDY |
| title_short | P491: DAY 14 MEASURABLE RESIDUAL DISEASE ASSESSMENT PREDICTS TREATMENT OUTCOMES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH INTENSIVE CHEMOTHERAPY - RESULTS OF THE PALG-AML1/2016 STUDY |
| title_sort | p491: day 14 measurable residual disease assessment predicts treatment outcomes in patients with acute myeloid leukemia treated with intensive chemotherapy - results of the palg-aml1/2016 study |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428723/ http://dx.doi.org/10.1097/01.HS9.0000968872.72243.64 |
| work_keys_str_mv | AT wierzbowskaagnieszka p491day14measurableresidualdiseaseassessmentpredictstreatmentoutcomesinpatientswithacutemyeloidleukemiatreatedwithintensivechemotherapyresultsofthepalgaml12016study AT plutaagnieszka p491day14measurableresidualdiseaseassessmentpredictstreatmentoutcomesinpatientswithacutemyeloidleukemiatreatedwithintensivechemotherapyresultsofthepalgaml12016study AT czyzanna p491day14measurableresidualdiseaseassessmentpredictstreatmentoutcomesinpatientswithacutemyeloidleukemiatreatedwithintensivechemotherapyresultsofthepalgaml12016study AT czemerskamagdalena p491day14measurableresidualdiseaseassessmentpredictstreatmentoutcomesinpatientswithacutemyeloidleukemiatreatedwithintensivechemotherapyresultsofthepalgaml12016study AT mikulskidamian p491day14measurableresidualdiseaseassessmentpredictstreatmentoutcomesinpatientswithacutemyeloidleukemiatreatedwithintensivechemotherapyresultsofthepalgaml12016study AT stelmachpiotr p491day14measurableresidualdiseaseassessmentpredictstreatmentoutcomesinpatientswithacutemyeloidleukemiatreatedwithintensivechemotherapyresultsofthepalgaml12016study AT liburamarta p491day14measurableresidualdiseaseassessmentpredictstreatmentoutcomesinpatientswithacutemyeloidleukemiatreatedwithintensivechemotherapyresultsofthepalgaml12016study AT giebelsebastian p491day14measurableresidualdiseaseassessmentpredictstreatmentoutcomesinpatientswithacutemyeloidleukemiatreatedwithintensivechemotherapyresultsofthepalgaml12016study AT kopinskaagnieszka p491day14measurableresidualdiseaseassessmentpredictstreatmentoutcomesinpatientswithacutemyeloidleukemiatreatedwithintensivechemotherapyresultsofthepalgaml12016study AT wozniczkakrzysztof p491day14measurableresidualdiseaseassessmentpredictstreatmentoutcomesinpatientswithacutemyeloidleukemiatreatedwithintensivechemotherapyresultsofthepalgaml12016study AT helbiggrzegorz p491day14measurableresidualdiseaseassessmentpredictstreatmentoutcomesinpatientswithacutemyeloidleukemiatreatedwithintensivechemotherapyresultsofthepalgaml12016study AT wojcikkarol p491day14measurableresidualdiseaseassessmentpredictstreatmentoutcomesinpatientswithacutemyeloidleukemiatreatedwithintensivechemotherapyresultsofthepalgaml12016study AT raznymalgorzata p491day14measurableresidualdiseaseassessmentpredictstreatmentoutcomesinpatientswithacutemyeloidleukemiatreatedwithintensivechemotherapyresultsofthepalgaml12016study AT sobasmarta p491day14measurableresidualdiseaseassessmentpredictstreatmentoutcomesinpatientswithacutemyeloidleukemiatreatedwithintensivechemotherapyresultsofthepalgaml12016study AT wrobeltomasz p491day14measurableresidualdiseaseassessmentpredictstreatmentoutcomesinpatientswithacutemyeloidleukemiatreatedwithintensivechemotherapyresultsofthepalgaml12016study AT szczepaniakandrzej p491day14measurableresidualdiseaseassessmentpredictstreatmentoutcomesinpatientswithacutemyeloidleukemiatreatedwithintensivechemotherapyresultsofthepalgaml12016study AT gillidia p491day14measurableresidualdiseaseassessmentpredictstreatmentoutcomesinpatientswithacutemyeloidleukemiatreatedwithintensivechemotherapyresultsofthepalgaml12016study AT dutkamagdalena p491day14measurableresidualdiseaseassessmentpredictstreatmentoutcomesinpatientswithacutemyeloidleukemiatreatedwithintensivechemotherapyresultsofthepalgaml12016study AT bieniaszewskamaria p491day14measurableresidualdiseaseassessmentpredictstreatmentoutcomesinpatientswithacutemyeloidleukemiatreatedwithintensivechemotherapyresultsofthepalgaml12016study AT maciejzauchajan p491day14measurableresidualdiseaseassessmentpredictstreatmentoutcomesinpatientswithacutemyeloidleukemiatreatedwithintensivechemotherapyresultsofthepalgaml12016study AT gromektomasz p491day14measurableresidualdiseaseassessmentpredictstreatmentoutcomesinpatientswithacutemyeloidleukemiatreatedwithintensivechemotherapyresultsofthepalgaml12016study AT husmarek p491day14measurableresidualdiseaseassessmentpredictstreatmentoutcomesinpatientswithacutemyeloidleukemiatreatedwithintensivechemotherapyresultsofthepalgaml12016study AT cichockaedyta p491day14measurableresidualdiseaseassessmentpredictstreatmentoutcomesinpatientswithacutemyeloidleukemiatreatedwithintensivechemotherapyresultsofthepalgaml12016study AT halkajanusz p491day14measurableresidualdiseaseassessmentpredictstreatmentoutcomesinpatientswithacutemyeloidleukemiatreatedwithintensivechemotherapyresultsofthepalgaml12016study AT patkowskaelzbieta p491day14measurableresidualdiseaseassessmentpredictstreatmentoutcomesinpatientswithacutemyeloidleukemiatreatedwithintensivechemotherapyresultsofthepalgaml12016study AT wozniakjolanta p491day14measurableresidualdiseaseassessmentpredictstreatmentoutcomesinpatientswithacutemyeloidleukemiatreatedwithintensivechemotherapyresultsofthepalgaml12016study AT obaraagata p491day14measurableresidualdiseaseassessmentpredictstreatmentoutcomesinpatientswithacutemyeloidleukemiatreatedwithintensivechemotherapyresultsofthepalgaml12016study AT kopaczagnieszka p491day14measurableresidualdiseaseassessmentpredictstreatmentoutcomesinpatientswithacutemyeloidleukemiatreatedwithintensivechemotherapyresultsofthepalgaml12016study AT dulikkatarzyna p491day14measurableresidualdiseaseassessmentpredictstreatmentoutcomesinpatientswithacutemyeloidleukemiatreatedwithintensivechemotherapyresultsofthepalgaml12016study AT holowieckijerzy p491day14measurableresidualdiseaseassessmentpredictstreatmentoutcomesinpatientswithacutemyeloidleukemiatreatedwithintensivechemotherapyresultsofthepalgaml12016study AT soinmichał p491day14measurableresidualdiseaseassessmentpredictstreatmentoutcomesinpatientswithacutemyeloidleukemiatreatedwithintensivechemotherapyresultsofthepalgaml12016study AT fendlerwojciech p491day14measurableresidualdiseaseassessmentpredictstreatmentoutcomesinpatientswithacutemyeloidleukemiatreatedwithintensivechemotherapyresultsofthepalgaml12016study AT rustaniandi p491day14measurableresidualdiseaseassessmentpredictstreatmentoutcomesinpatientswithacutemyeloidleukemiatreatedwithintensivechemotherapyresultsofthepalgaml12016study AT kanerjustin p491day14measurableresidualdiseaseassessmentpredictstreatmentoutcomesinpatientswithacutemyeloidleukemiatreatedwithintensivechemotherapyresultsofthepalgaml12016study AT menciatrinchantnuria p491day14measurableresidualdiseaseassessmentpredictstreatmentoutcomesinpatientswithacutemyeloidleukemiatreatedwithintensivechemotherapyresultsofthepalgaml12016study AT desaipinkal p491day14measurableresidualdiseaseassessmentpredictstreatmentoutcomesinpatientswithacutemyeloidleukemiatreatedwithintensivechemotherapyresultsofthepalgaml12016study AT leesangmin p491day14measurableresidualdiseaseassessmentpredictstreatmentoutcomesinpatientswithacutemyeloidleukemiatreatedwithintensivechemotherapyresultsofthepalgaml12016study AT samuelmichael p491day14measurableresidualdiseaseassessmentpredictstreatmentoutcomesinpatientswithacutemyeloidleukemiatreatedwithintensivechemotherapyresultsofthepalgaml12016study AT ritchieellen p491day14measurableresidualdiseaseassessmentpredictstreatmentoutcomesinpatientswithacutemyeloidleukemiatreatedwithintensivechemotherapyresultsofthepalgaml12016study AT guzmanmonica p491day14measurableresidualdiseaseassessmentpredictstreatmentoutcomesinpatientswithacutemyeloidleukemiatreatedwithintensivechemotherapyresultsofthepalgaml12016study AT robozgail p491day14measurableresidualdiseaseassessmentpredictstreatmentoutcomesinpatientswithacutemyeloidleukemiatreatedwithintensivechemotherapyresultsofthepalgaml12016study |